\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ examination\\:\\ slight\\ exophthalmos\\ with\\ downward\\ displacement\\ of\\ the\\ re\\,\\ lid\\ ptosis\\,\\ upper\\ lid\\ poorly\\ mobile\\ infiltrative\\ lesion\\ fixed\\ to\\ adjacent\\ tissues\\,\\ no\\ circumscribed\\ mass\\.\ \(0\)\
\-\ high\\-dose\\ chemotherapy\\ \\(vad\\,\\ vincristine\\,\\ adriamycin\\,\\ dexamethasone\\)\\,\\ followed\\ by\\ autologous\\ stem\\ cell\\ transplantation\\,\\ are\\ the\\ treatment\\ modalities\\ scheduled\\ for\\ this\\ patient\\.\ \(0\)\
\-\ followup\\ ocular\\ examination\\:\\ decreased\\ proptosis\\,\\ improved\\ motility\ \(0\)\
\-\ \\â\\€\\¢\\ a\\-b\\-scan\\:\\ large\\,\\ poorly\\ defined\\,\\ hypoechogenic\\ tumour\\ of\\ the\\ superior\\ extraconal\\ right\\ orbit\\,\\ with\\ medium\\-low\\ internal\\ reflectivity\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ contrast\\-enhanced\\ ct\\ scan\\ and\\ mri\\:\\ bulky\\ mass\\ \\(30x21x34\\ mm\\)\\ of\\ the\\ right\\ orbit\\ causing\\ downward\\ displacement\\ of\\ the\\ globe\\ and\\ medial\\ displacement\\ of\\ the\\ superior\\ rectus\\ muscle\\ and\\ optic\\ nerve\\.\\ the\\ lesion\\ showed\\ focal\\ erosions\\ of\\ the\\ orbital\\ roof\\,\\ without\\ extension\\ into\\ the\\ brain\\ parenchyma\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ skull\\ x\\-rays\\ assessed\\ changes\\ in\\ the\\ bone\\ structure\\ with\\ multiple\\ punched\\-out\\ lytic\\ lesions\\,\\ without\\ sclerosis\\ or\\ periosteal\\ reaction\\.\\ \ \(0\)\
\-\ ocullar\\ pathology\\:\\ immunohistochemical\\ stains\\ positive\\ for\\ monoclonal\\ light\\ kappa\\ chains\\,\\ cd\\ 138\\ \\(specific\\ marker\\ for\\ plasma\\ cells\\)\\ proliferation\\ index\\ \\(ki\\-67\\)\\ 20\\%\\.\ \(0\)\
\-\ non\\-secretory\\ myeloma\ \(0\)\
\-\ \\â\\€\\¢\\ plasmocytoma\ \(1\)\
\-\ \\â\\€\\¢\\ metastatic\\ carcinoma\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\\ and\\ sarcoma\\.\ \(1\)\
\-\ 62\\-year\\-old\\ woman\\ with\\ a\\ 5\\-month\\ history\\ of\\ slowly\\ progressive\\ swelling\\ and\\ ptosis\\ of\\ the\\ right\\ upper\\ eyelid\\.\\ \ \(1\)\
\-\ pmh\\:\\ systemic\\ hypertension\\ \ \(0\)\
\-\ va\\:\\ 20\\/25\\ in\\ the\\ affected\\ eye\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ 20\\/22\\ in\\ the\\ contralateral\\ eye\\.\\ \ \(1\)\
\-\ iop\\:\\ 14\\ mmhg\\ in\\ both\\ eyes\\.\\ \ \(0\)\
\-\ ocular\\ motility\\:\\ restricted\\ in\\ all\\ directions\\ of\\ gaze\\.\\ \ \(0\)\
\-\ pupillary\\ light\\ reaction\\:\\ preserved\\.\\ \ \(0\)\
\-\ fundus\\ examination\\:\\ mild\\ optic\\ nerve\\ head\\ elevation\\ and\\ retinal\\ venous\\ congestion\\.\ \(0\)\
\-\ presented\\ by\\ maria\\ antonietta\\ blasi\\,\\ m\\.d\\.\\ at\\ the\\ vzs\\-eops\\ combined\\ meeting\\ in\\ new\\ york\\ in\\ 2006\\.\ \(0\)\
\-\ malignant\\ plasma\\ cell\\ tumours\\ divided\\ according\\ to\\ site\\ of\\ origin\\:\\ multicentric\\,\\ such\\ as\\ multiple\\ myeloma\\ \\(mm\\)\\,\\ or\\ localized\\,\\ originating\\ at\\ bone\\ \\(solitary\\ plasmocytoma\\ of\\ bone\\)\\ or\\ from\\ soft\\ tissue\\ \\(extramedullary\\ plasmocytoma\\)\\.\\ \ \(0\)\
\-\ mm\\:\\ 15\\%\\ of\\ all\\ haematological\\ malignancies\\,\\ characterized\\ by\\ overproduction\\ of\\ a\\ serum\\ monoclonal\\ protein\\,\\ skeletal\\ destruction\\ with\\ osteolytic\\ lesions\\.\\ \ \(0\)\
\-\ incidence\\:\\ about\\ 5\\.0\\ and\\ about\\ 4\\.2\\ per\\ 100\\.000\\ person\\-years\\,\\ in\\ men\\ and\\ women\\ respectively\\.\\ \ \(0\)\
\-\ median\\ age\\ at\\ diagnosis\\:\\ 68\\ years\\ in\\ males\\ and\\ 70\\ in\\ females\\.\\ \ \(0\)\
\-\ risk\\ factors\\:\\ exposure\\ to\\ specific\\ agents\\ \\(pesticides\\,\\ petroleum\\ product\\,\\ asbestos\\,\\ rubber\\,\\ plastic\\ and\\ wood\\ products\\)\\,\\ high\\ dose\\ radiation\\,\\ long\\-standing\\,\\ chronic\\ infection\\ or\\ chronic\\ antigenic\\ stimulation\\,\\ viruses\\.\\ \ \(0\)\
\-\ the\\ most\\ common\\ sites\\ are\\ in\\ marrow\\ areas\\ of\\ most\\ active\\ haematopoiesis\\,\\ including\\,\\ in\\ order\\ of\\ frequency\\,\\ the\\ vertebrae\\,\\ ribs\\,\\ skull\\,\\ pelvis\\,\\ femur\\,\\ clavicle\\ and\\ scapula\\.\ \(0\)\
\-\ diagnosis\\:\\ a\\ constellation\\ of\\ radiological\\,\\ clinical\\,\\ laboratory\\ and\\ pathological\\ findings\\ are\\ combined\\ to\\ provide\\ diagnostic\\ criteria\\ for\\ mm\ \(0\)\
\-\ treatment\\:\\ high\\-dose\\ chemotherapy\\ with\\ haemopoietic\\ stem\\-cell\\ support\\,\\ suitable\\ for\\ patients\\ younger\\ than\\ 65\\ years\\ \\(only\\ about\\ a\\ third\\ of\\ all\\ myeloma\\ patients\\)\\.\\ \ \(0\)\
\-\ mm\\ is\\ still\\ an\\ incurable\\ neoplasm\\ with\\ a\\ median\\ survival\\ of\\ about\\ 4\\-5\\ years\\ obtained\\ with\\ high\\-dose\\ chemotherapy\\.\\ \ \(0\)\
\-\ its\\ incidence\\ shows\\ a\\ sharp\\ increase\\ of\\ about\\ 3\\%\\ per\\ year\\ and\\ the\\ global\\ mortality\\ rate\\ remains\\ stable\\.\\ \\ \ \(0\)\
\-\ about\\ 4\\%\\ of\\ mm\\ are\\ non\\-secretory\\:\\ plasma\\ cells\\ synthesise\\ but\\ do\\ not\\ secrete\\ ig\\ molecules\\,\\ leading\\ to\\ the\\ absence\\ of\\ a\\ m\\-component\\ \\(paraprotein\\)\\.\\ due\\ to\\ the\\ lack\\ of\\ serum\\ or\\ urine\\ monoclonal\\ ig\\,\\ the\\ diagnosis\\ can\\ be\\ missed\\.\\ \ \(0\)\
\-\ in\\ our\\ patient\\,\\ a\\ non\\-secretory\\ variant\\ of\\ mm\\ was\\ diagnosed\\:\\ \ \(0\)\
\-\ laboratory\\ tests\\ within\\ the\\ normal\\ range\\,\ \(1\)\
\-\ bone\\ marrow\\ sample\\ showed\\ \\<\\ 30\\%\\ of\\ plasma\\ cells\\ and\\ \ \(1\)\
\-\ lytic\\ bone\\ lesions\\ observed\\ only\\ on\\ the\\ skull\\.\\ \ \(1\)\
\-\ the\\ diagnosis\\ could\\ be\\ made\\ because\\ of\\ the\\ orbital\\ involvement\\,\\ which\\ was\\ the\\ first\\ manifestation\\ of\\ the\\ disease\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ as\\ solitary\\ plasmacytoma\\ will\\ progress\\ to\\ multiple\\ myeloma\\,\\ a\\ doubt\\ still\\ remains\\ about\\ the\\ onset\\ of\\ the\\ orbital\\ lesion\\.\\ \ \(0\)\
\-\ the\\ pathological\\ process\\ could\\ have\\ started\\ in\\ the\\ orbital\\ wall\\ as\\ solitary\\ plasmocytoma\\ of\\ the\\ bone\\,\\ although\\ the\\ orbital\\ bone\\ is\\ very\\ unusual\\ as\\ site\\ of\\ origin\\,\\ \ \(0\)\
\-\ or\\ it\\ could\\ have\\ developed\\ from\\ the\\ orbital\\ soft\\ tissue\\ as\\ extramedullary\\ plasmocytoma\\ and\\ have\\ filled\\ the\\ orbital\\ superior\\ extraconal\\ space\\.\\ \ \(1\)\
\-\ such\\ distinction\\ is\\ not\\ possible\\ now\\ that\\ the\\ disease\\ is\\ systemic\\ and\\ the\\ presence\\ of\\ a\\ non\\-secretory\\ form\\ of\\ myeloma\\ makes\\ the\\ clinical\\ picture\\ rather\\ confused\\.\\ \ \(0\)\
\-\ this\\ case\\ deserves\\ attention\\ for\\ the\\ uncommon\\ modality\\ of\\ presentation\\ of\\ a\\ rare\\ disease\\,\\ the\\ non\\-secretory\\ mm\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plasmocytoma\\:\\ 0\\.26055863146084257\ \(0\)\
\-\ the\\:\\ 0\\.25357956459027314\ \(0\)\
\-\ of\\:\\ 0\\.21043734554544324\ \(0\)\
\-\ orbital\\:\\ 0\\.20007419374074079\ \(0\)\
\-\ mm\\:\\ 0\\.18655988905551185\ \(0\)\
\-\ about\\:\\ 0\\.17076400784272983\ \(0\)\
\-\ myeloma\\:\\ 0\\.16919770021719566\ \(0\)\
\-\ plasma\\:\\ 0\\.15166751515660531\ \(0\)\
\-\ monoclonal\\:\\ 0\\.12875378977137503\ \(0\)\
\-\ bone\\:\\ 0\\.1244586490642212\ \(0\)\
\-\ dose\\:\\ 0\\.1217210875300177\ \(0\)\
\-\ in\\:\\ 0\\.11348791824267042\ \(0\)\
\-\ and\\:\\ 0\\.10773517809346586\ \(0\)\
\-\ ig\\:\\ 0\\.08991081891116785\ \(0\)\
\-\ solitary\\:\\ 0\\.08946597836515631\ \(0\)\
\-\ extraconal\\:\\ 0\\.08583585984758335\ \(0\)\
\-\ motility\\:\\ 0\\.08120348029491016\ \(0\)\
\-\ lid\\:\\ 0\\.08046613713097583\ \(0\)\
\-\ years\\:\\ 0\\.07989854262527289\ \(0\)\
\-\ displacement\\:\\ 0\\.07970345015649072\ \(0\)\
\-\ skull\\:\\ 0\\.07931615049553191\ \(0\)\
\-\ ptosis\\:\\ 0\\.07850277308216026\ \(0\)\
\-\ cells\\:\\ 0\\.0753206073472679\ \(0\)\
\-\ high\\:\\ 0\\.07407844672289428\ \(0\)\
\-\ downward\\:\\ 0\\.07367169541289767\ \(0\)\
\-\ extramedullary\\:\\ 0\\.07328437514378977\ \(0\)\
\-\ could\\:\\ 0\\.07110669247970977\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.06941413899269741\ \(0\)\
\-\ stem\\:\\ 0\\.06890874468211723\ \(0\)\
\-\ or\\:\\ 0\\.0680160367732596\ \(0\)\
\-\ pathological\\:\\ 0\\.06791465242718225\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06756891083329573\ \(0\)\
\-\ median\\:\\ 0\\.06744826711082966\ \(0\)\
\-\ ocular\\:\\ 0\\.0667825533585181\ \(0\)\
\-\ as\\:\\ 0\\.06545428401711832\ \(0\)\
\-\ combined\\:\\ 0\\.06462792682873503\ \(0\)\
\-\ superior\\:\\ 0\\.0635560717776953\ \(0\)\
\-\ 20\\:\\ 0\\.06306693945773172\ \(0\)\
\-\ examination\\:\\ 0\\.0625553408516524\ \(0\)\
\-\ remains\\:\\ 0\\.06207854439422215\ \(0\)\
\-\ orbit\\:\\ 0\\.06035827151041747\ \(0\)\
\-\ for\\:\\ 0\\.05925896502550717\ \(0\)\
\-\ poorly\\:\\ 0\\.058863448207397695\ \(0\)\
\-\ serum\\:\\ 0\\.05844025709648394\ \(0\)\
\-\ all\\:\\ 0\\.058192582102981116\ \(0\)\
\-\ systemic\\:\\ 0\\.05783348511065687\ \(0\)\
\-\ still\\:\\ 0\\.05773541709452863\ \(0\)\
\-\ to\\:\\ 0\\.057024634253026535\ \(0\)\
\-\ light\\:\\ 0\\.056444141413973505\ \(0\)\
\-\ lesions\\:\\ 0\\.05614311710861028\ \(0\)\
\-\ optic\\:\\ 0\\.05610051088732301\ \(0\)\
\-\ origin\\:\\ 0\\.05610051088732301\ \(0\)\
\-\ incidence\\:\\ 0\\.05610051088732301\ \(0\)\
\-\ cell\\:\\ 0\\.05592167034409305\ \(0\)\
\-\ reaction\\:\\ 0\\.05544278375101638\ \(0\)\
\-\ lytic\\:\\ 0\\.05489678240703608\ \(0\)\
\-\ marrow\\:\\ 0\\.054159439243101744\ \(0\)\
\-\ per\\:\\ 0\\.05408825612354448\ \(0\)\
\-\ site\\:\\ 0\\.05256267949447287\ \(0\)\
\-\ eye\\:\\ 0\\.052136102071111315\ \(0\)\
\-\ vad\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ reflectivity\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ 30x21x34\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ ocullar\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ maria\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ antonietta\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ blasi\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ haematological\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ antigenic\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ haematopoiesis\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ haemopoietic\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ incurable\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ synthesise\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ paraprotein\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ deserves\\:\\ 0\\.05211172629216851\ \(0\)\
\-\ with\\:\\ 0\\.05104559559012417\ \(0\)\
\-\ overproduction\\:\\ 0\\.04979553651583193\ \(0\)\
\-\ pesticides\\:\\ 0\\.04979553651583193\ \(0\)\
\-\ petroleum\\:\\ 0\\.04979553651583193\ \(0\)\
\-\ rubber\\:\\ 0\\.04979553651583193\ \(0\)\
\-\ viruses\\:\\ 0\\.04979553651583193\ \(0\)\
\-\ are\\:\\ 0\\.04945925771787025\ \(0\)\
\-\ specific\\:\\ 0\\.049385134216489546\ \(0\)\
\-\ have\\:\\ 0\\.048835125479285424\ \(0\)\
\-\ tumour\\:\\ 0\\.048152173716608314\ \(0\)\
\-\ multiple\\:\\ 0\\.04781521517641383\ \(0\)\
\-\ laboratory\\:\\ 0\\.04732566924615409\ \(0\)\
\-\ kappa\\:\\ 0\\.04687748249935187\ \(0\)\
\-\ molecules\\:\\ 0\\.04687748249935187\ \(0\)\
\-\ lesion\\:\\ 0\\.046867016603596774\ \(0\)\
\-\ nerve\\:\\ 0\\.04649302678182814\ \(0\)\
\-\ adriamycin\\:\\ 0\\.045835983940271725\ \(0\)\
\-\ hypoechogenic\\:\\ 0\\.045835983940271725\ \(0\)\
\-\ secrete\\:\\ 0\\.045835983940271725\ \(0\)\
\-\ chains\\:\\ 0\\.044955409455583926\ \(0\)\
\-\ wood\\:\\ 0\\.044955409455583926\ \(0\)\
\-\ suitable\\:\\ 0\\.044955409455583926\ \(0\)\
\-\ dexamethasone\\:\\ 0\\.04419262114104812\ \(0\)\
\-\ immunohistochemical\\:\\ 0\\.04419262114104812\ \(0\)\
\-\ iop\\:\\ 0\\.04419262114104812\ \(0\)\
\-\ doubt\\:\\ 0\\.04419262114104812\ \(0\)\
\-\ meeting\\:\\ 0\\.04351979416393514\ \(0\)\
\-\ multicentric\\:\\ 0\\.04351979416393514\ \(0\)\
\-\ showed\\:\\ 0\\.04340884217041686\ \(0\)\
\-\ tumours\\:\\ 0\\.04237347749217901\ \(0\)\
\-\ such\\:\\ 0\\.041921644991402246\ \(0\)\
\-\ cd\\:\\ 0\\.041876431364711524\ \(0\)\
\-\ 138\\:\\ 0\\.041876431364711524\ \(0\)\
\-\ directions\\:\\ 0\\.041876431364711524\ \(0\)\
\-\ by\\:\\ 0\\.04151341243778209\ \(0\)\
\-\ autologous\\:\\ 0\\.0414191932510579\ \(0\)\
\-\ va\\:\\ 0\\.0414191932510579\ \(0\)\
\-\ pupillary\\:\\ 0\\.0414191932510579\ \(0\)\
\-\ sample\\:\\ 0\\.0414191932510579\ \(0\)\
\-\ distinction\\:\\ 0\\.0414191932510579\ \(0\)\
\-\ clinical\\:\\ 0\\.04130264737173889\ \(0\)\
\-\ disease\\:\\ 0\\.04103503495256854\ \(0\)\
\-\ exophthalmos\\:\\ 0\\.040995856880023725\ \(0\)\
\-\ only\\:\\ 0\\.040715470337520744\ \(0\)\
\-\ bulky\\:\\ 0\\.04060174014745508\ \(0\)\
\-\ eyelid\\:\\ 0\\.039886754847149326\ \(0\)\
\-\ assessed\\:\\ 0\\.03925138654108013\ \(0\)\
\-\ product\\:\\ 0\\.038958377348231474\ \(0\)\
\-\ chronic\\:\\ 0\\.038683953175216564\ \(0\)\
\-\ stains\\:\\ 0\\.038679667103687136\ \(0\)\
\-\ plastic\\:\\ 0\\.038679667103687136\ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.038679667103687136\ \(0\)\
\-\ scan\\:\\ 0\\.038665540836453335\ \(0\)\
\-\ vincristine\\:\\ 0\\.03841392491661882\ \(0\)\
\-\ gaze\\:\\ 0\\.03841392491661882\ \(0\)\
\-\ retinal\\:\\ 0\\.03815999747391704\ \(0\)\
\-\ osteolytic\\:\\ 0\\.03815999747391704\ \(0\)\
\-\ transplantation\\:\\ 0\\.03791687878915133\ \(0\)\
\-\ asbestos\\:\\ 0\\.03768368613097503\ \(0\)\
\-\ global\\:\\ 0\\.03768368613097503\ \(0\)\
\-\ scapula\\:\\ 0\\.037459640675497695\ \(0\)\
\-\ york\\:\\ 0\\.03724405181203835\ \(0\)\
\-\ marker\\:\\ 0\\.03703630430446352\ \(0\)\
\-\ constellation\\:\\ 0\\.03703630430446352\ \(0\)\
\-\ manifestation\\:\\ 0\\.03703630430446352\ \(0\)\
\-\ at\\:\\ 0\\.03692416372683826\ \(0\)\
\-\ patients\\:\\ 0\\.036662545714189226\ \(0\)\
\-\ malignancies\\:\\ 0\\.036642187571894885\ \(0\)\
\-\ missed\\:\\ 0\\.03645487810710553\ \(0\)\
\-\ divided\\:\\ 0\\.036273515989927715\ \(0\)\
\-\ stimulation\\:\\ 0\\.035927202271589125\ \(0\)\
\-\ is\\:\\ 0\\.035695328501905994\ \(0\)\
\-\ attention\\:\\ 0\\.03560068901281474\ \(0\)\
\-\ mmhg\\:\\ 0\\.03529183396551993\ \(0\)\
\-\ roof\\:\\ 0\\.0351434508991611\ \(0\)\
\-\ clavicle\\:\\ 0\\.0351434508991611\ \(0\)\
\-\ proliferation\\:\\ 0\\.03499882477267127\ \(0\)\
\-\ modalities\\:\\ 0\\.034857770029145474\ \(0\)\
\-\ upper\\:\\ 0\\.034826652389935125\ \(0\)\
\-\ originating\\:\\ 0\\.034720114528126934\ \(0\)\
\-\ soft\\:\\ 0\\.03469593181362943\ \(0\)\
\-\ products\\:\\ 0\\.034454372341058616\ \(0\)\
\-\ confused\\:\\ 0\\.034454372341058616\ \(0\)\
\-\ without\\:\\ 0\\.034375527929271135\ \(0\)\
\-\ preserved\\:\\ 0\\.03420044489835684\ \(0\)\
\-\ picture\\:\\ 0\\.03420044489835684\ \(0\)\
\-\ tissue\\:\\ 0\\.0341875118309719\ \(0\)\
\-\ agents\\:\\ 0\\.03407759227389055\ \(0\)\
\-\ younger\\:\\ 0\\.03407759227389055\ \(0\)\
\-\ globe\\:\\ 0\\.03395732621359113\ \(0\)\
\-\ most\\:\\ 0\\.03391723386943931\ \(0\)\
\-\ fundus\\:\\ 0\\.033839540043439136\ \(0\)\
\-\ radiological\\:\\ 0\\.033839540043439136\ \(0\)\
\-\ rectus\\:\\ 0\\.03372413355541483\ \(0\)\
\-\ index\\:\\ 0\\.03372413355541483\ \(0\)\
\-\ respectively\\:\\ 0\\.03372413355541483\ \(0\)\
\-\ vertebrae\\:\\ 0\\.03372413355541483\ \(0\)\
\-\ fixed\\:\\ 0\\.033611012495252536\ \(0\)\
\-\ males\\:\\ 0\\.033611012495252536\ \(0\)\
\-\ infiltrative\\:\\ 0\\.03339127667925905\ \(0\)\
\-\ men\\:\\ 0\\.03317968112380217\ \(0\)\
\-\ progress\\:\\ 0\\.03317968112380217\ \(0\)\
\-\ provide\\:\\ 0\\.03297564418918334\ \(0\)\
\-\ proptosis\\:\\ 0\\.03287629513088863\ \(0\)\
\-\ according\\:\\ 0\\.03277864443052673\ \(0\)\
\-\ females\\:\\ 0\\.03277864443052673\ \(0\)\
\-\ erosions\\:\\ 0\\.032682634996334683\ \(0\)\
\-\ makes\\:\\ 0\\.032682634996334683\ \(0\)\
\-\ contralateral\\:\\ 0\\.03258821256781055\ \(0\)\
\-\ right\\:\\ 0\\.032410584422539454\ \(0\)\
\-\ criteria\\:\\ 0\\.032313963414367514\ \(0\)\
\-\ congestion\\:\\ 0\\.03222539688268105\ \(0\)\
\-\ modality\\:\\ 0\\.03222539688268105\ \(0\)\
\-\ mobile\\:\\ 0\\.03213818256472203\ \(0\)\
\-\ slowly\\:\\ 0\\.03213818256472203\ \(0\)\
\-\ sharp\\:\\ 0\\.03205227979007375\ \(0\)\
\-\ mortality\\:\\ 0\\.03205227979007375\ \(0\)\
\-\ ribs\\:\\ 0\\.03196764969602892\ \(0\)\
\-\ sites\\:\\ 0\\.031802060511646885\ \(0\)\
\-\ survival\\:\\ 0\\.031802060511646885\ \(0\)\
\-\ eyes\\:\\ 0\\.03164113643725454\ \(0\)\
\-\ support\\:\\ 0\\.03164113643725454\ \(0\)\
\-\ 68\\:\\ 0\\.031332281389959735\ \(0\)\
\-\ tests\\:\\ 0\\.031183898323600908\ \(0\)\
\-\ treatment\\:\\ 0\\.03104465434538454\ \(0\)\
\-\ exposure\\:\\ 0\\.03096830946014156\ \(0\)\
\-\ frequency\\:\\ 0\\.03096830946014156\ \(0\)\
\-\ re\\:\\ 0\\.030760561952566736\ \(0\)\
\-\ scheduled\\:\\ 0\\.030240892322796635\ \(0\)\
\-\ protein\\:\\ 0\\.030240892322796635\ \(0\)\
\-\ order\\:\\ 0\\.03011803969833035\ \(0\)\
\-\ characterized\\:\\ 0\\.02993857697497384\ \(0\)\
\-\ elevation\\:\\ 0\\.029707740442574352\ \(0\)\
\-\ destruction\\:\\ 0\\.029707740442574352\ \(0\)\
\-\ skeletal\\:\\ 0\\.02954053552437729\ \(0\)\
\-\ pmh\\:\\ 0\\.029485870735310293\ \(0\)\
\-\ uncommon\\:\\ 0\\.029485870735310293\ \(0\)\
\-\ women\\:\\ 0\\.02932494666091795\ \(0\)\
\-\ localized\\:\\ 0\\.029272297192692063\ \(0\)\
\-\ unusual\\:\\ 0\\.02922012854824197\ \(0\)\
\-\ urine\\:\\ 0\\.029168432024695067\ \(0\)\
\-\ observed\\:\\ 0\\.029016091613623143\ \(0\)\
\-\ leading\\:\\ 0\\.02896620110554019\ \(0\)\
\-\ improved\\:\\ 0\\.028916742555328435\ \(0\)\
\-\ variant\\:\\ 0\\.028916742555328435\ \(0\)\
\-\ our\\:\\ 0\\.028867708547264316\ \(0\)\
\-\ rather\\:\\ 0\\.028867708547264316\ \(0\)\
\-\ followup\\:\\ 0\\.028770885435004532\ \(0\)\
\-\ periosteal\\:\\ 0\\.028675676116629314\ \(0\)\
\-\ slight\\:\\ 0\\.028535772955985125\ \(0\)\
\-\ form\\:\\ 0\\.028489889762598183\ \(0\)\
\-\ restricted\\:\\ 0\\.02800809712046872\ \(0\)\
\-\ 65\\:\\ 0\\.027883457407965058\ \(0\)\
\-\ lack\\:\\ 0\\.027883457407965058\ \(0\)\
\-\ structure\\:\\ 0\\.027842507936086683\ \(0\)\
\-\ factors\\:\\ 0\\.027563797691542345\ \(0\)\
\-\ started\\:\\ 0\\.02744839120351804\ \(0\)\
\-\ sarcoma\\:\\ 0\\.027335270143355742\ \(0\)\
\-\ do\\:\\ 0\\.027008756884581358\ \(0\)\
\-\ 70\\:\\ 0\\.026903938771905386\ \(0\)\
\-\ affected\\:\\ 0\\.026801009377006534\ \(0\)\
\-\ causing\\:\\ 0\\.026767107634387076\ \(0\)\
\-\ femur\\:\\ 0\\.026733405903212278\ \(0\)\
\-\ parenchyma\\:\\ 0\\.026470719306944224\ \(0\)\
\-\ be\\:\\ 0\\.02643748131971457\ \(0\)\
\-\ filled\\:\\ 0\\.026219583179648537\ \(0\)\
\-\ increase\\:\\ 0\\.026158487122770156\ \(0\)\
\-\ absence\\:\\ 0\\.025979024399413637\ \(0\)\
\-\ from\\:\\ 0\\.025883365807336377\ \(0\)\
\-\ stable\\:\\ 0\\.025776537438176962\ \(0\)\
\-\ not\\:\\ 0\\.025728166870614622\ \(0\)\
\-\ tissues\\:\\ 0\\.025691907344132132\ \(0\)\
\-\ pathology\\:\\ 0\\.025580982948817093\ \(0\)\
\-\ range\\:\\ 0\\.025286600741452777\ \(0\)\
\-\ circumscribed\\:\\ 0\\.0252346692304785\ \(0\)\
\-\ made\\:\\ 0\\.025132201427181453\ \(0\)\
\-\ progressive\\:\\ 0\\.024957189979768236\ \(0\)\
\-\ hypertension\\:\\ 0\\.02493262036397802\ \(0\)\
\-\ mass\\:\\ 0\\.02489378188014019\ \(0\)\
\-\ diagnostic\\:\\ 0\\.024835385218620477\ \(0\)\
\-\ third\\:\\ 0\\.024811332859444334\ \(0\)\
\-\ rate\\:\\ 0\\.024692567108244773\ \(0\)\
\-\ rare\\:\\ 0\\.02459930092440931\ \(0\)\
\-\ process\\:\\ 0\\.024439661840881654\ \(0\)\
\-\ 14\\:\\ 0\\.024328304964447066\ \(0\)\
\-\ active\\:\\ 0\\.024197480310882206\ \(0\)\
\-\ developed\\:\\ 0\\.02417596455337514\ \(0\)\
\-\ its\\:\\ 0\\.024111899281530423\ \(0\)\
\-\ diagnosed\\:\\ 0\\.023604245115982143\ \(0\)\
\-\ involvement\\:\\ 0\\.023584848062149884\ \(0\)\
\-\ presence\\:\\ 0\\.023413176238839335\ \(0\)\
\-\ very\\:\\ 0\\.02337571756779554\ \(0\)\
\-\ including\\:\\ 0\\.02331998613193898\ \(0\)\
\-\ risk\\:\\ 0\\.023283131637234472\ \(0\)\
\-\ venous\\:\\ 0\\.023264793172480508\ \(0\)\
\-\ defined\\:\\ 0\\.02324651339091407\ \(0\)\
\-\ malignant\\:\\ 0\\.0232282919181598\ \(0\)\
\-\ sclerosis\\:\\ 0\\.023210128383413502\ \(0\)\
\-\ muscle\\:\\ 0\\.023138046330899137\ \(0\)\
\-\ extension\\:\\ 0\\.02306686252050074\ \(0\)\
\-\ obtained\\:\\ 0\\.02304920430902116\ \(0\)\
\-\ pelvis\\:\\ 0\\.02279067933941938\ \(0\)\
\-\ because\\:\\ 0\\.02277385332765208\ \(0\)\
\-\ was\\:\\ 0\\.022712920868625804\ \(0\)\
\-\ new\\:\\ 0\\.02254334950306974\ \(0\)\
\-\ presentation\\:\\ 0\\.02243149421443155\ \(0\)\
\-\ this\\:\\ 0\\.02239410882236491\ \(0\)\
\-\ now\\:\\ 0\\.022368546724972724\ \(0\)\
\-\ neoplasm\\:\\ 0\\.022244695220744348\ \(0\)\
\-\ 30\\:\\ 0\\.022229400896039423\ \(0\)\
\-\ although\\:\\ 0\\.022183762089778014\ \(0\)\
\-\ areas\\:\\ 0\\.02212347206454507\ \(0\)\
\-\ possible\\:\\ 0\\.02207866848691053\ \(0\)\
\-\ 15\\:\\ 0\\.022019471823853436\ \(0\)\
\-\ followed\\:\\ 0\\.02200476801428105\ \(0\)\
\-\ first\\:\\ 0\\.021990101955224065\ \(0\)\
\-\ internal\\:\\ 0\\.021960882316758534\ \(0\)\
\-\ swelling\\:\\ 0\\.021931811379386712\ \(0\)\
\-\ space\\:\\ 0\\.021690505300336647\ \(0\)\
\-\ radiation\\:\\ 0\\.02159403258997023\ \(0\)\
\-\ positive\\:\\ 0\\.021472343155665756\ \(0\)\
\-\ medial\\:\\ 0\\.021210859207232858\ \(0\)\
\-\ patient\\:\\ 0\\.021197024630564054\ \(0\)\
\-\ adjacent\\:\\ 0\\.021122096071568987\ \(0\)\
\-\ will\\:\\ 0\\.020973067788417822\ \(0\)\
\-\ onset\\:\\ 0\\.02092424332995351\ \(0\)\
\-\ age\\:\\ 0\\.020457663551315487\ \(0\)\
\-\ brain\\:\\ 0\\.020313877549375286\ \(0\)\
\-\ decreased\\:\\ 0\\.020184289530293154\ \(0\)\
\-\ year\\:\\ 0\\.020084580160233616\ \(0\)\
\-\ wall\\:\\ 0\\.0198222952452463\ \(0\)\
\-\ changes\\:\\ 0\\.019693475303709348\ \(0\)\
\-\ infection\\:\\ 0\\.01968368536666897\ \(0\)\
\-\ on\\:\\ 0\\.01968291848877263\ \(0\)\
\-\ focal\\:\\ 0\\.019491329588066545\ \(0\)\
\-\ carcinoma\\:\\ 0\\.019491329588066545\ \(0\)\
\-\ head\\:\\ 0\\.019434863623873505\ \(0\)\
\-\ lymphoma\\:\\ 0\\.01940683857895567\ \(0\)\
\-\ shows\\:\\ 0\\.019125022910651844\ \(0\)\
\-\ presented\\:\\ 0\\.019002170286185567\ \(0\)\
\-\ due\\:\\ 0\\.018730906178083203\ \(0\)\
\-\ common\\:\\ 0\\.01847985907169098\ \(0\)\
\-\ mild\\:\\ 0\\.01847194163887135\ \(0\)\
\-\ than\\:\\ 0\\.01847194163887135\ \(0\)\
\-\ both\\:\\ 0\\.0181714210355191\ \(0\)\
\-\ metastatic\\:\\ 0\\.017871660007649184\ \(0\)\
\-\ into\\:\\ 0\\.017322029758446676\ \(0\)\
\-\ can\\:\\ 0\\.017099975215898757\ \(0\)\
\-\ woman\\:\\ 0\\.01697077103901728\ \(0\)\
\-\ mri\\:\\ 0\\.016726638523941892\ \(0\)\
\-\ it\\:\\ 0\\.01668019577328891\ \(0\)\
\-\ case\\:\\ 0\\.016370732146984857\ \(0\)\
\-\ large\\:\\ 0\\.016327083973861335\ \(0\)\
\-\ but\\:\\ 0\\.016113709892711738\ \(0\)\
\-\ findings\\:\\ 0\\.01608238023356849\ \(0\)\
\-\ within\\:\\ 0\\.015007996835775469\ \(0\)\
\-\ which\\:\\ 0\\.014817069885454994\ \(0\)\
\-\ that\\:\\ 0\\.014140998396262074\ \(0\)\
\-\ normal\\:\\ 0\\.013304547850631369\ \(0\)\
\-\ an\\:\\ 0\\.012460685747220455\ \(0\)\
\-\ history\\:\\ 0\\.012449647237766467\ \(0\)\
\-\ ct\\:\\ 0\\.012405705275974658\ \(0\)\
\-\ no\\:\\ 0\\.01059651879690029\ \(0\)\
